anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Endoscopic submucosal dissection (ESD) of fibrotic colorectal lesions is difficult and has a high complication rate. There are only a few reports on the utility of orthodontic rubber band (ORB) traction in reducing the difficulty of this procedure. This study aimed to investigate the risk factors for perforation when applying ORB traction during ESD of fibrotic colorectal lesions. We continuously collected the clinical data of 119 patients with fibrotic colorectal lesions who underwent ESD with ORB and clip traction between January 2019 and January 2024. Possible risk factors for perforation were analyzed. The median ORB-ESD operative time was 40 (IQR 28-62) min, and the en bloc and R0 resection rates were 94.1% and 84.0%, respectively. Perforation occurred in 16 of 119 patients (13.4%). The lesion size, lesion at the right half of the colon or across an intestinal plica, the degree of fibrosis, operation time, and the surgeon's experience were associated with perforation during ORB-ESD (P < 0.05). Multivariate logistic regression analysis showed that lesions in the right colon (OR 9.027; 95% CI 1.807-45.098; P = 0.007) and those across an intestinal plica (OR 7.771; 95% CI 1.298-46.536; P = 0.025) were independent risk factors for perforation during ORB-ESD. ORB-ESD is an effective and feasible approach to treat fibrotic colorectal lesions. Adequate preoperative evaluation is required for lesions in the right colon and across intestinal plicas to mitigate the risk of perforation.
OBJECTIVE: Post-COVID-19 Condition (PCC) is a prevalent, persistent and debilitating phenomenon occurring three or more months after resolution of acute COVID-19 infection. Fatigue and depressive symptoms are commonly reported in PCC. We aimed to further characterize PCC by assessing the relationship between fatigue and depressive symptom severity in adults with PCC.
METHODS: A post hoc analysis was conducted on data retrieved from a randomized, double-blinded, placebo-controlled study evaluating vortioxetine for cognitive deficits in persons with PCC. We sought to determine the relationship between baseline fatigue [i.e. Fatigue Severity Scale (FSS) total score] and baseline depressive symptom severity [i.e. 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16) total score] in adults with PCC.
RESULTS: The statistical analysis included baseline data from 142 participants. After adjusting for age, sex, education, employment status, history of major depressive disorder (MDD) diagnosis, self-reported physical activity, history of documented acute SARS-CoV-2 infection and body mass index (BMI), baseline FSS was significantly correlated with baseline QIDS-SR-16 (β = 0.825, p = .001).
CONCLUSION: In our sample, baseline measures of fatigue and depressive symptoms are correlated in persons living with PCC. Individuals presenting with PCC and fatigue should be screened for the presence and severity of depressive symptoms. Guideline-concordant care should be prescribed for individuals experiencing clinically significant depressive symptoms. Fatigue and depressive symptom severity scores were not pre-specified as primary objectives of the study. Multiple confounding factors (i.e. disturbance in sleep, anthropometrics and cognitive impairment) were not collected nor adjusted for in the analysis herein.
TRIAL REGISTRATION: Unrestricted Research Grant from H. Lundbeck A/S, Copenhagen, Denmark. ClinicalTrials.gov Identifier: NCT05047952.
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a fatal progressive lung disease entailing significant impairment in health-related quality of life (HRQoL) and high socioeconomic burden. The course of IPF includes episodes of acute exacerbations (AE-IPF) leading to poor outcomes. This study aimed to compare management, costs and HRQoL of patients with AE-IPF to patients without AE-IPF during one year in Spain.
MATERIALS AND METHODS: In a 12-month, prospective, observational, multicenter study of IPF patients, healthcare resource use was recorded and costs related to AE-IPF were estimated and compared between patients with and without AE-IPF. HRQoL was measured with the St. George's Respiratory Questionnaire (SGRQ), EuroQoL 5 dimensions 5 levels questionnaire (EQ-5D-5L), EQ-5D visual analogue scale (EQ-VAS) and the Barthel Index.
RESULTS: 204 IPF patients were included: 22 (10.8%) experienced ≥ 1 acute exacerbation, and 182 (89.2%) did not. Patients with exacerbations required more primary care visits, nursing home visits, emergency visits, hospital admissions, pharmacological treatments and transport use (p < 0.05 for all comparisons). Likewise, patients with exacerbations showed higher annual direct health AE-IPF-related costs. In particular, specialized visits, emergency visits, days of hospitalization, tests, palliative care, transport in ambulance and economic aid (p < 0.05 for all comparisons). Exploratory results showed that patients with AE-IPF reported a non-significant but substantial decline of HRQoL compared with patients without AE-IPF, although causality can be inferred.
CONCLUSION: We observed significantly higher resource use and cost consumption and lower HRQoL among patients suffering exacerbations during the study. Thus, preventing or avoiding AE-IPF is key in IPF management.
PURPOSE:A carcinostatic agent, containing eicosapentaenoic acid or an ester, phospholipid or glycerid containing the eicosapentaenoic acid as a fatty acid constituent component and having very little side effect. CONSTITUTION:A carcinostatic agent obtained by incorporating eicosapentaenoic acid or an ester, phospholipid or glycerid (generically named EPA) as a fatty acid constituent component therein. The agent is particularly effective for treating cancer in digestive organs, e.g. colonic cancer and is capable of inhibiting the multiplication of cancer and preventing relapse or metastasis by cancerous cells left after surgical operation. In application thereof, it is administered to the proximity of cancerous tissues 1 - several times a day or systemically administered. The dose thereof is 10-10,000mg/human/day expressed in terms of ethyl eicosapentaenoate and the amount EPA in the pharmaceutical is 0.1-20wt%. Examples of the dosage form include capsule, granule, emulsion, suppository, injection, etc.
PURPOSE OF REVIEW: Surgical procedures on obese patients are dramatically increasing worldwide over the past few years. In this review, we discuss the physiopathology of predominantly respiratory system in obese patients, the importance of preoperative evaluation, preoxygenation and intraoperative positive end expiratory pressure (PEEP) titration to prevent pulmonary complications and the optimization of airway management and oxygenation to reduce or prevent postoperative respiratory complications.
RECENT FINDINGS: Many patients are coming to preoperative clinic with medication history of glucagon-like-peptide 1 agonists ( GLP-1) agonists and it has raised many questions regarding Nil Per Os (NPO)/perioperative fasting guidelines due to delayed gastric emptying caused by these medications. American Society of Anesthesiologists (ASA) has come up with guiding document to help with such situations. Ambulatory surgery centers are doing more obesity cases in a safe manner which were deemed unsafe at one point . Quantitative train of four (TOF) monitoring, better neuromuscular reversal agents and gastric ultrasounds seemed to have made a significant impact in the care of obese patients in the perioperative period.
SUMMARY: Obese patients are at higher risk of perioperative complications, mainly associated with those related to the respiratory function. An appropriate preoperative evaluation, intraoperative management, and postoperative support and monitoring is essential to improve outcome and increase the safety of the surgical procedure.
Participants in this arm who completed the main study continued with the same dose (240 mg (40 mg/mL) starting dose and 240 mg (60 mg/mL) at months 1, 3, 6, and 9) in the extension study (240 mg (60 mg/mL) every three months). A protocol amendment in June 2006 changed the dosage to 360 mg or 480 mg (60 mg/mL).
BACKGROUND AND AIMS: Lysyl oxidase (LOX) catalyzes the crosslinking of collagen and elastin to maintain tensile strength and structural integrity of the vasculature. Excessive LOX activity increases vascular stiffness and the severity of occlusive diseases. Herein, we investigated the mechanisms by which LOX controls atherogenesis and osteogenic differentiation of vascular smooth muscle cells (SMC) in hyperlipidemic mice.
METHODS: Gene inactivation of Lox in SMC was achieved in conditional knockout mice after tamoxifen injections. Atherosclerosis burden and vascular calcification were assessed in hyperlipidemic conditional [Loxf/fMyh11-CreERT2ApoE-/-] and sibling control mice [Loxwt/wtMyh11-CreERT2ApoE-/-]. Mechanistic studies were performed with primary aortic SMC from Lox mutant and wild type mice.
RESULTS: Inactivation of Lox in SMCs decreased > 70 % its RNA expression and protein level in the aortic wall and significantly reduced LOX activity without compromising vascular structure and function. Moreover, LOX deficiency protected mice against atherosclerotic burden (13 ± 2 versus 23 ± 1 %, p < 0.01) and plaque calcification (5 ± 0.4 versus 11.8 ± 3 %, p < 0.05) compared to sibling controls. Interestingly, gene inactivation of Lox in SMCs preserved the contractile phenotype of vascular SMC under hyperlipidemic conditions as demonstrated by single-cell RNA sequencing and immunofluorescence. Mechanistically, the absence of LOX in SMC prevented excessive collagen crosslinking and the subsequent activation of the pro-osteogenic FAK/β-catenin signaling axis.
CONCLUSIONS: Lox inactivation in SMC protects mice against atherosclerosis and plaque calcification by reducing SMC modulation and FAK/β-catenin signaling.
The present invention belongs to the field of Chinese medicine technology. The medicament for treating gout and reducing uric acid is a medicinal preparation prepared from equisetum hiemale extract and a proper amount of medicinal auxiliary materials. The extract is obtained by leaching, heating reflux or supercritical extraction of herba Equiseti hiemalis, and the solvent used in the extract is ethanol with concentration of above 60%, or acetone, diethyl ether, petroleum ether, chloroform, ethyl acetate, or liquid CO 2 . The pharmaceutical preparation of the invention comprises various administration routes of oral administration, injection, cavity, transdermal administration and the like. The invention relates to a natural medicine for treating gout and reducing blood uric acid, which is prepared by taking a horsetail as a single effective component and adding a pharmaceutical adjuvant. The medicinal preparation prepared by the invention has no obvious toxic or side effect and adverse reaction, and provides a safe, quick and effective novel medicinal product for treating gout and reducing blood uric acid. The effect is superior to that of common uric acid lowering drugs such as allopurinol and the like, andhas less adverse reaction.
Major Depressive Disorder (MDD) is associated with functional impairment and disability, and results in a significant burden on the affected individual, his or her family, and society in general. Psychopharmacological therapy has been shown to be effective, but may be accompanied by significant side effects. The investigators propose an alternative model, based on the relationship between symptoms, brain metabolism, and neural activity as recorded with electroencephalography (EEG). Subjects with MDD often have decreased brain metabolism, accompanied by increased EEG activity in the alpha band. The investigators hypothesis is that a gentle, non-significant risk, sinusoidal magnetic field above the subject's scalp, which oscillates at precisely his or her Intrinsic Alpha Frequency (IAF) can take advantage of this relationship to reduce symptoms without the significant side effects associated with pharmaceuticals. The investigators propose a 4-week, sham controlled, randomized, double-blind multi-center feasibility study to determine the efficacy of synchronized low energy magnetic fields delivered at the subject's IAF to treat MDD. Treatment will be given concomitant to the subject's existing medication, and will occur 5 days per week at the clinical site. Target enrollment is 45 adult subjects diagnosed with MDD.
Healthy subjects will be matched to KCNQ1 subjects. The matching factors will be age per decade (18-28 years, \> 28-38 years, \> 38-48 years), gender and body mass index (BMI: ≤ 24.9 kg/m2; 25-29.9 kg/m2; \> 30 kg/m2).
Diabetes Mellitus (DM) is a serious chronic disease that negatively affects the quality of life. To control the course of the disease and to reduce its complications, insulin treatment is planned for the whole life of Type 1 diabetic patients, and frequently for approximately 40% of Type 2 diabetic patients. Frequent or incorrect administration of insulin injections may lead to the development of complications such as regional pain, ecchymosis, or hematoma on the injection site. It is emphasized that the pain caused by repeated insulin injections negatively affects the psychological well-being of the individuals as well as their physical comfort. Pain control is one of the main tasks of nurses. By alleviating pain, the patient's acceptance of treatment increases, and thus the quality of life improves. In the literature, lavender is reported to have the ability to heal burns and insect bites as well as analgesic, wound healing, antibacterial, antifungal, sedative, and antidepressant effects. The main components of lavender, such as lavender and linalyl acetate and linalool, are also recommended as topical analgesics in animal models. Whatever the cause, acute pain is a serious problem for individuals with chronic illnesses. Therefore, this study evaluated the effect of topically administered lavender aromatherapy on the pain of insulin injection in diabetic patients.
Advise the patient to read theFDA-approved patient labeling (Patient Information).

Dosing and Administration

Instruct patients to swallow guanfacine extended-release tablets whole with water, milk or other liquid. Tablets should not be crushed, chewed or broken prior to administration because this may increase the rate of release of the active drug. Patients should not take guanfacine extended-release tablets together with a high-fat meal, since this can raise blood levels of guanfacine extended-release tablets. Instruct the parent or caregiver to supervise the child or adolescent taking guanfacine extended-release tablets and to keep the bottle of tablets out of reach of children. 

Advise patients not to abruptly discontinue guanfacine extended-release tablets as abrupt discontinuation can result in clinically significant rebound hypertension. Concomitant stimulant use and abrupt discontinuation of guanfacine extended-release tablets may increase this hypertensive response. Instruct patients on how to properly taper the dose to minimize the risk of rebound hypertension [see Dosage and Administration (2.5) and Warnings and Precautions (5.4] . 

Adverse Reactions

Advise patients that sedation can occur, particularly early in treatment or with dose increases. Caution against operating heavy equipment or driving until they know how they respond to treatment with guanfacine extended-release tablets [see Warnings and Precautions (5.2)] . Headache and abdominal pain can also occur. If any of these symptoms persist, or other symptoms occur, the patient should be advised to discuss the symptoms with the health care provider. 

Advise patients to avoid becoming dehydrated or overheated, which may potentially increase the risks of hypotension and syncope [see Warnings and Precautions (5.1)] . Advise patients to avoid use with alcohol.
Placebo Treatment A: Form=capsule route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
Fractures of the carpals, metacarpals and phalanges account for approximately 15-19% of fractures in adults, with 59% of these occurring in the phalanges, 33% in the metacarpals and 8% in the carpal bones \[1\]. The single most common fracture site in the hand is the sub capital region of the fifth metacarpal bone (boxer's fracture) \[2\], which usually results from a direct blow to the metacarpal head \[3\]. Most hand fractures are caused by accidental falls or other sports-related injuries \[4\]. Hand fractures are among the most common fractures of upper extremity \[5, 6\]. Hand fractures can be treated conservatively or surgically, depending on the severity, location and type of fracture. The main objective of both operative and non-operative treatments is to provide fracture stability for early mobilization \[7\]. Surgical fixation is mainly indicated for displaced fractures because casts are often not sufficient to maintain reduction \[8\]. Open reduction with internal fixation (ORIF), using pins or plates, has historically been used to stabilize hand fractures which have rotational deformity or lateral angulation \[9\]. Open reduction may result in scarring, joint stiffness and tendon adhesion \[7\]. Closed reduction with internal fixation (CRIF), using percutaneous K wire or screws, is now used to treat the majority of unstable closed simple hand fractures \[10\]. It is generally considered percutaneous Kirschner wire (K wire) fixation may not provide adequate stabilization to allow for early mobilization \[8\] .
The control group recieves a health consultation that highlights the importance of physical activity and balance exercise according to standard practice within the HAI project. They are asked to return after 4 weeks for follow up.
Standard care completed with stepwise anti-seizure treatment according to protocols for clinically overt status epilepticus. This consists of a stepwise approach consisting of 3 potential steps. Each next step will be taken as soon as possible (within 30 minutes of ESE first diagnosis or recurrence) if the previous step was insufficiently effective to sustainably suppress ESE.
PURPOSE:To obtain a cosmetic, containing dihydromyricetin in flavones and having excellent thermal-oxidative stability, photooxidative stability and ultraviolet ray protecting effects even without adding well-known antioxidants or ultraviolet ray absorbers. CONSTITUTION:A cosmetic containing dihydromyricetin expressed by the formula. The dihydromyricetin may be a synthetic substance or natural extract. The amount thereof blended is 0.001-10wt.%, preferably 0.005-5wt.% based on the total weight of the cosmetic. When vitamins (particularly preferably L- ascorbic acid or esters thereof and tocopherol or esters thereof) are further added to this cosmetic, the dihydromyricetin exhibits better effects by synergistic effects thereof. This cosmetic is used as toilet water, liquid hairdressing, hair tonic, perfume, cream, milky lotion, rinse, lipstick, foundation, shampoo, pomade, etc.
A non-randomized, open-label design will be utilized to test the feasibility, acceptability, and preliminary efficacy of the Expanding PrEP Implementation in Communities of PWID (EPIC-P) intervention among high-risk people who inject drugs (PWID) with opioid dependence (N=100). Since the aim of this pilot study is to establish whether the EPIC-P intervention is feasible/acceptable among at-risk PWID in a community-based setting, proposed is a non-comparative design. With the hopes to target PWID who are not linked with existing harm reduction services, proposed is to recruit participants using respondent driven sampling (RDS), a chain referral method with demonstrated success in recruiting hard-to-reach populations. Initial RDS participants, called "seeds," will be carefully recruited from the community where the study team leadership have built a well-established relationship. Participants enrolled in the study will be assessed at baseline and will be followed for 9 months (with follow-up assessments at 3- and 6-months) by trained research assistants. Importantly, structured interviews will be conducted at follow-up visits to examine the barriers and facilitators and feedback about optimal implementation of the EPIC-P intervention.
PURPOSE: A pharmaceutical composition containing telmisartan as an active ingredient with enhanced stability is provided to save time and costs by a simple manufacturing process and to improve drug compliance by minimizing formulation volume. CONSTITUTION: A pharmaceutical composition contains telmisartan or a pharmaceutically acceptable salt thereof as an active ingredient and also contains an alkali metal phosphate compound as a solubilizing agent. The composition additionally contains a soluble diluent. The alkali metal phosphate compound is Na_3PO_4 or K_3PO_4. A method for manufacturing the pharmaceutical composition comprises the steps of: dissolving a first pharmaceutical ingredient and a phosphate compound in a solvent to prepare a first liquid; dispersing a second pharmaceutical ingredient and a surfactant in a solvent to prepare a second liquid; spraying the first liquid to a pharmaceutically acceptable excipient and preparing granules; spraying the second liquid to the granules and preparing double-coated granules; and filling or tableting the double-coated granules. [Reference numerals] (AA) Elution rate (%); (BB) Example 2; (C1) Comparative example 1; (C2) Comparative example 2; (C3) Comparative example 3; (DD) Time (min)
PURPOSE:To remarkably improve the dissolution property of a drug by simply mixing a scarcely soluble drug to porous cellulose particles having specified specific surface area and pore volume and absorbing the drug to the particle by sublimation. CONSTITUTION:The dissolution property of a scarcely soluble drug can be improved by mixing the drug to porous cellulose particles having an average particle diameter of <=100mum and a specific surface area of >=20m<2>/g and containing 0.3-1.2cm<3>/g of pores having diameter of >=0.01mum and absorbing the drug to the particle by sublimation. The cellulose particles can be produced by dispersing fine cellulose particles (e.g. ramie, cotton linter, wood pulp or crystalline cellulose) in an organic solvent (e.g. acetone, methanol, n-hexane or benzene) and granulating and drying by spray-drying process. The drug to be used in the present process is a sublimable molecular crystal scarcely soluble in water, e.g. benzoic acid, caffeine, camphor or salicylic acid.
A method and a system for acquiring a 3D ultrasound image. The method includes receiving a request to capture a plurality of ultrasound image for a medical test corresponding to a medical condition. The method further includes determining a body part corresponding to the medical test. Further, the method includes identifying an imaging site particular to the medical test. Furthermore, the method includes providing a navigational guidance to the user in real time for positioning a handheld ultrasound device. Subsequently, the user is assisted to capture the plurality of ultrasound image of the imaging site in real time using deep learning. Further, the plurality of ultrasound images of the imaging site is captured. Finally, the method includes converting the plurality of ultrasound image to a 3-Dimensional (3D) ultrasound image in real time.